skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Why is this clinical and research excellence important?
In the past 10 years’ investment in R&D by pharma has increased from $70billion to over $100billion, a CAGR of 6%. The result is an increase in pharma’s collective pipeline by 54%. Yet getting a new drug to market has not become no less risky. Less than 10% of candidates starting phase I trials will make it to FDA approval, and of those that do, it will cost on average $1billion.


Behind these eye watering figures lie crucial decisions about R&D strategy. How does each pharma company best utilize their finite resources to get the best return on investment in a competitive and fast changing healthcare market?

Where do you rank?
With ownership of the world’s leading R&D databases, Pharma Intelligence is in a unique position to create the definitive index of clinical and research excellence. Based on a series of key R&D indicators this index allows you to create your own versions by adjusting indicator weighting and compare this to our analysts.


Go to the CARE index now